Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCPHARMACEUTICALS INC.

(SCPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ScPharmaceuticals : Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021

09/13/2021 | 10:09am EDT

BURLINGTON, Mass. - scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced that data from its recently-completed FREEDOM-HF clinical trial will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021. In the FREEDOM-HF study, heart failure (HF) patients with mild to moderate volume overload (despite oral diuretic use) and treated with subcutaneous FUROSCIX were successfully managed in the outpatient setting resulting in significantly reduced HF-related and overall healthcare costs through reduction of HF-related hospitalizations and rehospitalizations.

'We are pleased to present these very compelling results from the FREEDOM-HF study at this year's HFSA meeting,' stated John Tucker, chief executive officer of scPharmaceuticals. 'In this study, there was a highly statistically significant and meaningful cost savings associated with treating HF patients with FUROSCIX. These data provide a strong pharmacoeconomic case for the broad adoption of FUROSCIX as a viable HF treatment pre-admission or post-discharge, if approved by the Food and Drug Administration (FDA).

Following our Type-C meeting with the FDA in June, we are aligned with the agency on the regulatory path forward, are well financed with more than $90 million on hand as of June 30, 2021, and remain on track to re-submit our New Drug Application (NDA) in the fourth quarter of this year.'

FREEDOM-HF was a prospective clinical trial evaluating 30-day heart failure-related and overall costs of treating congestion in patients with chronic HF. Patients were treated with FUROSCIX, the Company's investigational product, post-discharge from the emergency department compared to a historical comparator group that was managed in the hospital setting.

The HFSA Annual Scientific Meeting 2021 is being held virtually and in a hybrid format in Denver, Colorado from September 10-14, 2021. A copy of the poster can be accessed under the News and Events section of the Company's website.

Late-breaking HFSA Poster Presentation Details and Data:

Title: Significantly Reduced Healthcare Costs with Home FUROSCIX Versus in Hospital IV Diuresis: Results from the FREEDOM-HF Study

Presenter: Daniel Bensimhon, MD

Session: Session PV.01 - Poster Viewing Session I

Date: Friday, September 10, 2021

Time: 6:36-6:46pm MT (8:36-8:46pm ET)

90 subjects were enrolled in the study, 24 in the FUROSCIX group and 66 in the comparator group.

Comparators were hospitalized for ?72 hours and were selected from a claims database matched to seven variables associated with HF-related hospitalization and severity. Baseline patient characteristics (key matching variables) were similar between the study groups, as were the incidence of co-morbidities and HF medication use.

FUROSCIX utilization led to a statistically significant reduction in 30-day HF-related and overall healthcare costs.

Mean 30-day HF-related costs were $17,753 lower in the FUROSCIX treated group ($2,920) versus the comparator group ($20,673, p-value

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about SCPHARMACEUTICALS INC.
09/13SCPHARMACEUTICALS : Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Soci..
AQ
09/13SCPHARMACEUTICALS : September 2021 Corporate Presentation
PU
09/10SCPHARMACEUTICALS : Data show statistically significant and meaningful reduction in both h..
PU
09/10SCPHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/10scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failur..
GL
09/10ScPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failur..
CI
09/09SCPHARMACEUTICALS : SVB Leerink Starts scPharmaceuticals at Market Perform with $6 Price T..
MT
09/01SCPHARMACEUTICALS : to Present at the Virtual H.C. Wainwright 23rd Annual Global Investmen..
AQ
08/11SCPHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/11SCPHARMACEUTICALS : Announced positive top-line results from the FREEDOM-HF study demonstr..
PU
More news
Analyst Recommendations on SCPHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -33,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,33x
Yield 2021 -
Capitalization 176 M 176 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 21,9x
Nbr of Employees 27
Free-Float 91,5%
Chart SCPHARMACEUTICALS INC.
Duration : Period :
scPharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCPHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 6,42 $
Average target price 10,67 $
Spread / Average Target 66,1%
EPS Revisions
Managers and Directors
John H. Tucker President, Chief Executive Officer, CFO & Director
Jack A. Khattar Chairman
Mike Hassman Senior Vice President-Technical Operations
John Mohr Senior VP-Clinical Development & Medical Affairs
Mette Kirstine Agger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SCPHARMACEUTICALS INC.21.36%176
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979